Investigations revealed that a French pharmaceutical company fell victim to a business e-mail impersonation scam by the syndicate in March 2020. The firm transferred more than $10 million for what ...
Ultragenyx Pharmaceutical RARE during the recent three months, expressing a mix of bullish and bearish perspectives. The table below provides a snapshot of their recent ratings, showcasing how ...
The drugmaker posted revenue of $117.1 million in the period, surpassing Street forecasts. Three analysts surveyed by Zacks expected $114.8 million. BioCryst expects full-year revenue in the range of ...
Revenue missed analyst estimates by 5.7%. Earnings per share (EPS) exceeded analyst estimates by 87%. Looking ahead, revenue is forecast to grow 56% p.a. on average during the next 3 years, compared ...